Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances

This article was originally published in Start Up

Executive Summary

FDA's effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms. This article first appeared in the May 2011 issue of The RPM Report.

You may also be interested in...



Forest Labs Had Effective "Co-Sponsor" for Ceftaroline Review

FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data.

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

Rx Vial Size: FDA Stresses Safety Issues Amid Push To Find Savings For Payors

There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel